论文部分内容阅读
目的研究自体CIK细胞过继性免疫治疗晚期恶性肿瘤的临床疗效。方法从34例晚期肿瘤患者外周血中分离出单个核细胞,加入含有IFN-γ、IL-2、抗CD3单抗等细胞因子的培养基中进行培养。扩增后的CIK细胞总数在4.5~6×109之间,分三次回输给患者。检测患者回输前后瘤体变化,免疫学指标和肿瘤标志物的改变,观察患者临床症状的改善和毒副反应。结果 34例接受CIK治疗的患者中,外周血中CD3+、CD4+、CD4+/CD8+和NK细胞(CD16、CD56)均显著上升(P<0.05),CD8+下降。有效率(CR+PR+MR)为79.4%。24例CEA升高者19例下降,8例CA125升高者6例下降,4例CA199升高者均下降。患者临床症状改善,毒副反应轻。结论自体CIK细胞过继性免疫治疗能显著提高肿瘤患者细胞免疫功能,改善临床症状,提高生活质量。
Objective To study the clinical efficacy of adoptive immunotherapy of autologous CIK cells in advanced malignant tumors. Methods Mononuclear cells were isolated from the peripheral blood of 34 patients with advanced cancer and cultured in a medium containing cytokines such as IFN-γ, IL-2 and anti-CD3 monoclonal antibody. The total number of CIK cells after amplification was between 4.5 and 6 × 109, and was transfused into the patients three times. The changes of tumor before and after reinfusion were detected, the changes of immunological indexes and tumor markers were observed, and the clinical symptoms and side effects of the patients were observed. Results Among the 34 patients treated with CIK, the levels of CD3 +, CD4 +, CD4 + / CD8 + and NK cells (CD16, CD56) in peripheral blood increased significantly (P <0.05) and CD8 + decreased. The effective rate (CR + PR + MR) was 79.4%. Twenty-four patients with elevated CEA decreased in 19 patients, 6 patients in 8 patients with elevated CA125 decreased, and 4 patients with elevated CA199 decreased. Patients with improved clinical symptoms, mild side effects. Conclusion Adoptive immunotherapy of CIK cells can significantly improve cellular immune function, improve clinical symptoms and improve quality of life in cancer patients.